FHA
ANIK icon

First Horizon Advisors’s Anika Therapeutics ANIK Stock Holding History

First Horizon Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-61
Closed -$3K – 1437
2017
Q3 		$3K Hold
61
– – ﹤0.01% 1252
2017
Q2 		$3K Buy
61
+2
+3% +$92 ﹤0.01% 1236
2017
Q1 		$2K Buy
+59
New +$2.82K ﹤0.01% 1364

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

First Horizon Advisors's ANIK Position: Q4 2017 in Review

First Horizon Advisors sold out of Anika Therapeutics (ANIK) in Q4 2017, closing a stake of 61 shares — an estimated $3K sold.

First Horizon Advisors first reported a position in ANIK in Q1 2017 and held it in 3 quarters. The position peaked at $3K in Q3 2017. 172 funds tracked by Wall St. Rank hold ANIK as of Q4 2017.

  • First Horizon Advisors reported no remaining Anika Therapeutics position as of Q4 2017 after selling out during the quarter.
  • First Horizon Advisors sold 61 Anika Therapeutics shares in Q4 2017, an estimated $3K.
  • First Horizon Advisors first reported a position in Anika Therapeutics in Q1 2017 and held it in 3 quarters.
  • First Horizon Advisors's Anika Therapeutics position peaked at $3K in Q3 2017.
  • 172 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2017.

Based on First Horizon Advisors's 13F filing for Q4 2017, filed 25 Jan 2018.